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The ATR/CHK1 pathway is a key effector of cellular response to DNA damage and 
therefore is a critical regulator of genomic stability. While the ATR/CHK1 pathway is 
often inactivated by mutations, CHK1 itself is rarely mutated in human cancers. Thus, 
cellular levels of CHK1 likely play a key role in the maintenance of genomic stability and 
preventing tumorigenesis. Glucose deprivation is observed in many solid tumors due to 
high glycolytic rates of cancer cells and insufficient vascularization, yet cancer cells have 
devised mechanisms to survive in conditions of low glucose. Although CHK1 
degradation through the ubiquitin-proteasome pathway following glucose deprivation has 
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been previously reported, the detailed molecular mechanisms remain elusive.  Here we 
show that CHK1 is ubiquitinated and degraded upon glucose deprivation by the Skp1-
Cullin-F-box (β-TrCP) E3 ubiquitin ligase. Specifically, CHK1 contains a β-TrCP 
recognizable degron domain, which is phosphorylated by AMPK in response to glucose 
deprivation, allowing for β-TrCP to recognize CHK1 for subsequent ubiquitination and 
degradation. Our results provide a novel mechanism by which glucose metabolism 
regulates a DNA damage effector, and imply that glucose deprivation, which is often 
found in solid tumor microenvironments, may enhance mutagenesis, clonal expansion, 
and tumor progression by triggering CHK1 degradation. 1 Introduction 
Cancer cells have a high rate of glycolysis that they rely on for the generation of ATP 
even in the presence of sufficient oxygen. This is a characteristic of cancer cells known as 
the Warburg effect (Warburg, 1956; Annibaldi, 2010; Hanahan, 2011). Glucose levels in 
solid tumors are relatively low and poorly distributed due to high glycolytic rate of cancer 
cells and poor distribution of glucose as a result of insufficient and disorganized 
vascularization (Skinner, 1990; Bergers, 2003). Although dependence on glucose for 
growth makes cancer cells vulnerable to glucose deprivation, they are still able to survive 
in conditions of low glucose. Previous studies have shown that due to the Warburg effect 
of cancer metabolism, solid tumors are often in a lactic acidosis microenvironment, 
which prolongs cancer cell survival under conditions of glucose deprivation (Denko, 
2008; Wu, 2012). Furthermore, lactic acidosis alters cancer cell metabolism (Chen, 
2008), induces chromosomal instability (Dai, 2013), and promotes tumor angiogenesis 
(Vegran, 2011). However, mechanistically, how cancer cells survive low glucose 
conditions and how these conditions promote tumorigenesis and metastatic 
transformation remains largely elusive. 
 
Checkpoint kinase 1 (CHK1) is a Ser/Thr protein kinase that is involved in initiating 
checkpoints during the cell cycle in response to DNA damage. CHK1 is a key 
downstream regulator of the ataxia-telangiectasia-mutated-and-Rad3-related kinase 
(ATR) response pathway to DNA damage, and is phosphorylated directly by ATR 
leading to its activation (Liu, 2000). Similarly, checkpoint kinase 2 (CHK2) is 
phosphorylated by ataxia telangiectasia mutated (ATM), and activation of the CHK1 and 
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CHK2 kinases lead to phosphorylation of downstream factors to trigger cellular 
responses to DNA damage, including transcriptional regulation, abnormal energy 
consumption, cell-cycle arrest or delay, DNA repair, or cell death under extensive DNA 
damage conditions (Zeman, 2014). Inactivation of these checkpoint pathways are 
associated with tumorigenesis and malignant transformation (Bartek, 2003). However, 
CHK1 itself is rarely mutated in cancer (Zhang, 2014). It is possible that CHK1 loss-of-
function mutations do not allow for clonal expansion of cancer cells, and therefore these 
cells die off early during tumorigenesis. Furthermore, CHK1 overexpression is associated 
with tumor growth potentially through increased survival in response to replication stress, 
as well as increased resistance to chemotherapy (Zhang, 2014), suggesting that CHK1 
levels play a critical role during tumorigenesis. Therefore, it is important to elucidate 
mechanistically how CHK1 protein abundance is controlled, particularly under 
pathological tumor microenvironment conditions, which could provide a sound rationale 
for targeting tumors via correcting their growth environment.  
 
CHK1 kinase activity is controlled through multiple pathways including phosphorylation 
as well as ubiquitination. In fact, these modifications have been shown to work in concert 
to regulate the activation as well as subsequent inactivation through degradation of 
CHK1. For instance, activating phosphorylation of CHK1 at Ser317 and Ser345 in response 
to DNA damage and replication stress is also utilized by the E3 ubiquitin ligase 
machinery to recognize CHK1 as a substrate for ubiquitination and subsequent 
degradation, thereby turning off the checkpoint signal (Zhang, 2005; Leung-Pineda, 
2009; Zhang, 2009). In addition to regulation of CHK1 degradation in response to 
genotoxic stress, CHK1 is also degraded in response to glucose deprivation, which 
appears independent of phosphorylation at Ser317 and Ser345 (Kim, 2011). While CHK1 
has been previously shown to be targeted by a variety of E3 ubiquitin ligases including 
CRL4 (CDT2) (Huh, 2013), SCFFbx6 (Zhang, 2009), and Cul4A/DDB1 (Leung-Pineda, 
2009); the E3 ubiquitin ligase responsible for regulating CHK1 under glucose deprivation 
remains elusive. The linkage between reduced CHK1 functionality and glucose 
deprivation may provide an explanation, in part, for why the tumor microenvironment, 
which often contains low glucose concentrations, enhances genomic instability and 
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mutation rates during tumorigenesis (Yuan, 1998; Papp-Szabo, 2005; McGranahan, 
2017). 
 
Here we report that an AMP-activated protein kinase (AMPK)/beta-transducin repeat-
containing protein (β-TrCP) signaling pathway is involved in degrading CHK1 under 
glucose deprivation conditions. Specifically, glucose deprivation activates AMPK, which 
phosphorylates CHK1 at Ser280 for subsequent β-TrCP binding and ubiquitination by 
SCFβ-TrCP 
 
for targeted degradation. Our study suggests that the AMPK-CHK1-β-TrCP 
axis plays a role in regulating cellular levels of CHK1 under tumor growth environments 
that favor tumorigenesis.  
2 Materials and Methods 
2.1 Cell culture and transfection  
HEK293, MDA-MB-231, SK-BR3, and H1299 cells were cultured in DMEM high 
glucose media (C11995500BT from Gibco) containing 10% Fetal Bovine Serum (FBS), 
1% penicillin/streptomycin. For glucose deprivation, we washed the cells twice with PBS 
followed by culturing cells in glucose-free DMEM media (11966-025 from Gibco) 
containing 10% FBS, 1% penicillin/streptomycin, and 1mM sodium pyruvate. Cell 
transfections were performed using Lipofectamine 3000 (for siRNA) or PolyJet In Vitro 
DNA Transfection Reagent (for plasmid DNA). AMPK double knockout (DKO) MEFs 
were provided by Dr. Zong-Ping Xia. 
 
2.2 Antibodies and chemicals 
Antibodies were obtained from commercial sources: β-Actin (A5441), FLAG (F1804 
and F7425 from Sigma), HA (11867423001 from Roche), CHK1 (8408 from Santa 
Cruz), CUL1 (SC-11384 from Santa Cruz), NEDD8 (ab81264 from Abcam), p-CHK1 
Ser280 (2347), CHK2 (2662), p-AMPK Thr172 (2535), AMPK (D5A2), p-AKT Ser473 
(4060), AKT (4691), p-ERK Thr202/Tyr204 (9101), ERK (4696), p-GSK3β Ser9 
(9323),  GSK3α/β (5676), p-ACC Ser79 (3661), ACC (3676), PARP (9542), β-TrCP1 
(4394), MEK1/2 (9216), and Vimentin (3390) (Cell Signaling Technology). Compounds 
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were obtained from commercial sources: MLN4924 (B1036 from Apexbio), Compound 
C (S7840 from Selleckchem), AICAR (S1802 from Selleckchem), UCN-01 (ALX-380-
222-MC25 from Enzo Biochem), and LY294002 (L9908 from Sigma). 
 
2.3 Constructs 
The CHK1-HA, β-TrCP1 wild-type, β-TrCP1-∆F plasmids were previously described 
(Zhao, 2011). The AMPK-WT-MYC-α2 and AMPK-DN-MYC-α1 plasmid were a kind 
gift from Dr. Wei Liu and subcloned into pIRES2-EGFP. Mutations were generated using 
QuikChange Site-Directed Mutagensis Kit (Agilent) according to manufacturer’s 
instructions. FLAG-FBXW7, FLAG-SKP2 and His-Ubiqutin were described previously 
(Inuzuka, 2012; Dai, 2014; Li, 2016).  
 
2.4 Immunoprecipitation and Immunoblotting 
For experiment in Fig. 2C, HEK293 were transfected with FLAG tagged β-TrCP1, 
FBXW7, or SKP2 in pIRES2-EGFP, and grown under glucose deprivation conditions 
combined with 10 µM MG132 for 12 hr before harvesting. Cells were lysed in lysis 
buffer (50 mM Tris-HCl, pH8.0, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP-40) 
supplemented with 1X Halt Protease and Phosphatase Inhibitor Cocktail (Thermo 
Scientific) and incubated for 30 minutes at 4°C. Lysates were cleared by centrifugation at 
21,000 x g for 10 minutes at 4°C. Cleared lysates were then subjected to 
immunoprecipitation (IP) with bead-conjugated FLAG antibody (Sigma) with constant 
rotation at 4°C for 4 hr. The immunoprecipitates were washed with lysis buffer 6 times 
for 5 minutes and assessed by immunoblotting (IB). 
 
For experiment in Fig. 2D, cells were grown under normal glucose or glucose deprivation 
conditions together with MG132 (20 µM) for 2 hr. Following lysis, IPs were carried out 
by adding either 10 µl mouse IgG (2025 from Santa Cruz) or 20 µl CHK1 Ab (8408 from 
Santa Cruz) to each sample and incubating with constant rotation at 4°C for 16 hrs. 
Protein G beads (17-0618-01 from GE Healthcare) were added to each IP and incubated 
for an additional 2 hrs at 4°C and subsequently assessed by IB. 
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For direct IB analysis, cells were washed twice in PBS and lysed in RIPA buffer with 
phosphatase inhibitors and protease inhibitor cocktail.  
 
2.5 In vivo ubiquitination assay  
HEK293 were transfected with indicated plasmids and grown in glucose-free media with 
20 µM MG132 for indicated times. Cells were then lysed in 6 M guanidine denaturing 
solution and incubated with Ni-NTA resin (Qiagen) as described previously (Zhao, 
2011). 
 
2.6 In vitro kinase assay 
In vitro kinase assays were performed as previously described (Su, 2017) with minor 
modifications. Immunoprecipitated HA-CHK1 was eluted from HA-agarose beads by 
incubating with 80 µl (1mg/ml) HA peptide while shaking at 1100 rpm for 45 min at 4℃. 
HEK293 cells transfected with FLAG-vector or FLAG-AMPK WT/DN and cultured in 
glucose free media for 12 hr before harvest. Immunoprecipitated FLAG-vector or FLAG-
AMPK WT/DN was incubated with HA-CHK1 (1 µl) in kinase reaction buffer (50 mM 
HEPES, 80 mM NaCl, 1 mM dithiothreitol, 0.02‰ Brij-35, 0.1 mM ATP, 0.3 mM AMP, 
and 25 mM MgCl2
 
) at 30℃ while shaking at 1100 rpm for 90 min. Reactions were 
stopped by addition of 15 µl loading buffer and boiled at 100℃ for 8 min. For reactions 
involving compound C treatment, 293 cells were transfected with control vector or 
FLAG-AMPK WT for 48 hrs and pretreated with or without 20 μM Compound C for 1 
hr. Cells cultured in glucose free media were pretreated with or without 20 μM 
Compound C for 4 hr before harvest. Cells were processed and reactions were carried out 
as described above. 
2.7 RNA isolation and RT-PCR:  
RNA was isolated from cells by Trizol followed by analysis for CHK1 mRNA levels 
using SYBR Green RT-PCR Kit (Thermo Fisher). The primers used for q-PCR are as 
follows: GAPDH: For AGGGCATCCTGGGCTACAC and Rev 
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GCCAAATTCGTTGTCATACCAG; and CHK1: For 
CTGCAATGCTCGCTGGAGAAT and Rev GGGCTGGTATCCCATAAGGAAAGA. 
Relative expression levels were determined by normalization to the housekeeping gene 
GAPDH using the comparative Ct (2∆∆Ct
 
) method. 
2.8 siRNA and shRNA silencing:  
Cells were transfected with the following siRNA oligonucleotides by Lipofectamine 
3000: siCtrl: ATTGTATGCGATCGCAGAC; siβ-TrCP (recognizes both β-TrCP1 and β-TrCP2) : AAGTGGAATTTGTGGAACATC; siLKB1: 
CATCTACACTCAGGACTTCAC; siAKT1: TGCCCTTCTACAACCAGGA; siCUL1: 
GGTCGCTTCATAAACAACA 
 
To knockdown AMPK, we utilized two separate shRNAs, one targeting AMPK α1 and 
the other targeting AMPK α2. Each shRNA were individually packaged into lentivirus, 
and cells were subsequently infected with a mixture of each lentiviral preparation.  
Sequences of the AMPK α1 and AMPK α2 shRNAs are as follows, PRKAA1: 
CAAAGTCGACCAAATGATA; PRKAA2: GCATACCATCTTCGTGTAAGA.  
 
All shRNA vectors were packaged into lentivirus that were subsequently incubated with 
target cells followed by selection with puromycin (Invitrogen) to remove uninfected cells. 
Viral production, cellular transduction, and selection were performed as previously 
described (Li, 2016).  
 
2.9 Detection of CHK1 Phosphorylation Sites In Vivo: 
To map CHK1 phosphorylation sites in vivo, nanoscale-microcapillary reversed phase 
liquid chromatography tandem mass spectrometry (LC-MS/MS). HEK293T cells were 
transfected with HA-CHK1 without or with FLAG-AMPK. 48 hours post-transfection, 
cells were transferred to glucose-free media and 5 uM MG132 for 16 hours to trigger 
AMPK activation but block the CHK1 degradation. Cells were then harvested, lysed and 
HA-CHK1 was immunoprecipitated with agarose conjugated HA antibody (Sigma). HA-
CHK1 was then subjected to LC-MS/MS as previously described (Gao, 2011). 
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2.10 Subcellular Fractionation: 
MDA-MB231, H1299 and 293T cells are cultured in normal glucose or in glucose-free 
media for 3 hr prior to harvest. Cells were fractionated into nuclear, cytoplasm and 
membrane fractions using the Cell Fractionation Kit (Cell Signaling Technology, #9038). 
Proteins were separated and immunoblotted as described above.  
 
2.11 Statistical Analysis 
Paired two-tailed Student’s t test was used for statistical analysis for data presented in Fig. 
4B.3 Results 
3.1 CHK1 protein abundance is reduced in response to glucose deprivation 
 
Previous studies have shown that CHK1 is targeted for degradation following DNA 
damage as well as under glucose deprivation (Kim, 2011), but detailed molecular 
mechanisms behind this degradation remains elusive. We first assessed the regulation of 
CHK1 protein abundance by glucose deprivation in breast cancer cell lines MDA-MB-
231 and SK-BR3 and in the lung cancer cell line H1299 by growing cells in glucose-free 
media over a period of 20 hours. We found that glucose deprivation reduced levels of 
CHK1 protein in each cell line starting as early as 1 hr of glucose deprivation in MDA-
MB-231 and H1299 cells and was more pronounced after 10-20 hrs of glucose 
deprivation in all cells tested without affecting the levels of CHK2, AMPK, AKT, ERK, 
or GSK3α/β (Fig. 1A). To assess if degradation of CHK1 was through a proteasome-
dependent pathway, each of the cell lines were placed under glucose deprivation and 
treated with cycloheximide (CHX), in the absence or presence of the proteasome 
inhibitor MG132 and harvested at the indicated time points. We observed that the loss of 
CHK1 in response to glucose deprivation was blocked by MG132 (Fig. 1B). These 
results are consistent with recent results demonstrating that glucose deprivation leads to 
degradation of CHK1 (Kim, 2011) in each of the cell lines tested.  
 
Glucose deprivation or inhibition of glycolysis has been shown to cause increased 
degradation of HuR, Sp1, and Cyclin D1 through the E3 ubiquitin ligase beta-transducin 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
repeat-containing protein (β-TrCP) (Wei, 2008; Wei, 2009; Chu, 2012). β-TrCP is a 
member of the Cullin-RING E3 ubiquitin ligases (CRL), which require neddylation of the 
Cullin scaffold protein for their activity. Therefore we treated cells with the neddylation 
inhibitor MLN4924 to determine if glucose deprivation was controlling CHK1 
degradation through a CRL based mechanism. We observed that MLN4924 treatment 
blocked the loss of CHK1 protein caused by glucose deprivation in the three cell lines 
tested in a dose (Fig. 1C) and time-dependent manner (Fig. 1D). By assessing the rate of 
CHK1 protein decline following CHX treatment, which blocks new protein synthesis, we 
found that MLN4924 blocked the effect of glucose deprivation on CHK1 protein 
abundance by prolonging the protein half-life of CHK1 (Fig. 1E). These results indicate 
that a Cullin-RING E3 ubiquitin ligase regulates CHK1 stability in response to glucose 
deprivation. 
 
3.2 β-TrCP1 interacts with CHK1 to regulate its degradation in response to glucose 
deprivation 
 
Our results suggest that glucose deprivation regulates CHK1 protein abundance through 
increasing its degradation via activating a CRL pathway. To determine which Cullin is 
involved in regulating CHK1 degradation, we carried out co-immunoprecipitation assays 
to determine which Cullin scaffold protein interacted with CHK1. We assessed 
interaction between CHK1 and each of the 7 Cullin factors, and found that CUL1 
specifically interacted with CHK1 in HEK293 cells (Fig. 2A). Furthermore, depleting 
CUL1 reduced the degradation of CHK1 in response to glucose deprivation (Fig. 2B). 
Cullin 1 is a scaffold protein for Skp1-Cullin-F-box (SCF) E3 ubiquitin ligase complexes, 
which target proteins for ubiquitination by recognizing and binding to degron domains in 
substrate molecules through the substrate recognition subunit (the F-box protein) within 
the SCF complexes (Lau, 2012). Of the ~70 F-box proteins that function in SCF 
complexes, β-TrCP, FBXW7 (F-box/WD repeat-containing protein 7), and SKP2 (S-
phase kinase-associated protein 2) are the most extensively studied and each have strong 
links by their regulating numerous oncogenes and tumor suppressors for degradation 
(Wang, 2014). Given that β-TrCP, a substrate recognition protein for the SCF complex, 
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has previously been shown to regulate stability of various proteins in response to glucose 
deprivation (Wei, 2008; Wei, 2009; Chu, 2012) and that β-TrCP forms a SCF complex 
with Cullin 1 (Zhao, 2013), we went on to test if β-TrCP also interacted with CHK1. We 
observed that β-TrCP interacted with CHK1, whereas other key F-box proteins that serve 
as a substrate recognition protein in SCF complexes, namely FBXW7 and SKP2, do not 
interact with CHK1 (Fig. 2C). More importantly, we observed that CHK1 interacted with β-TrCP at the endogenous level, which was enhanced by culturing the cells under glucose 
deprivation conditions (Fig. 2D). Furthermore, glucose deprivation also promoted 
ubiquitination of CHK1 (Fig. S1), suggesting glucose deprivation resulted in enhanced 
binding and subsequent ubiquitination of CHK1, promoting its degradation.  
 
Moreover, depletion of β-TrCP1 and β-TrCP2 using a siRNA that targets both mRNAs 
also blocked the loss of CHK1 protein in response to glucose deprivation (Fig. 2E), 
which was due in part to prolonging the half-life of CHK1 (Fig. 2F). We also observed 
that co-expressing CHK1 with β-TrCP1 resulted in an increase in ubiquitinated species of 
CHK1, which was not observed when we expressed a form of β-TrCP1 lacking the F-
Box domain (β-TrCP1-∆F) (Fig. 2G). β-TrCP1-∆F is a dominant-negative mutant that is 
unable to incorporate into the SCF E3 ligase but maintains the capacity to bind to its 
substrates (Yamoah, 2008). These results combined indicate that CHK1 interacts with, 
and is ubiquitinated by, β-TrCP in response to glucose deprivation, suggesting that β-
TrCP1 is a major regulatory mechanism controlling CHK1 degradation due to glucose 
starvation.  
 
3.3 Degradation of CHK1 is largely dependent on a β-TrCP degron domain 
 
SCF complexes typically recognize substrates for ubiquitination through binding to a 
degron motif in the substrate protein recognized by the substrate recognition protein, for 
instance β-TrCP typically recognize substrate which contain a DSGxx(x)S degron (Lau, 
2012). By scanning the CHK1 protein sequence, we found that CHK1 contained a highly 
conserved amino acid sequence conforming to the β-TrCP degron motif consensus, 
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(T/S)SGxxS (located at amino acids 279-284 in human CHK1) (Fig. 3A), which is 
similar to the classical degron recognized by β-TrCP. Furthermore, it has been reported 
that β-TrCP could bind a TSGxxS motif (Setoyama, 2007). To assess the contribution of 
the putative β-TrCP degron domain in CHK1 in regulating its binding to, and degradation 
by, β-TrCP in response to glucose deprivation, we mutated key amino acids within the 
degron domain, namely Ser280 to alanine (S280A), Ser284 to alanine (S284A), Thr279 and 
Ser284
 
 to alanine (T279A/S284A), or a triple mutant (T279A/S280A/S284A), and 
assessed interaction with β-TrCP and stability of these CHK1 mutants. We found that 
mutation of these conserved amino acids within the β-TrCP degron motif reduced the 
interaction of CHK1 with β-TrCP1 under glucose deprivation conditions (Fig. 3B). On 
the contrary, mutating these same residues in CHK1 to glutamic acid (S to E) to mimic 
phosphorylation lead to both an increase in interaction with β-TrCP as well as an increase 
in ubiquitination (Fig. S2A-B). Furthermore, when we subjected cells to glucose 
deprivation in the presence of CHX where we observed that the mutant CHK1 had a 
prolonged half-life in response to glucose deprivation (Fig. 3C and Fig. S2C). Finally, 
mutation of the β-TrCP degron domain in CHK1 resulted in a decrease in CHK1 
ubiquitination in cells (Fig. 3D). These results together indicate that β-TrCP regulates 
CHK1 degradation in response to glucose deprivation by binding to a β-TrCP degron 
domain within CHK1.  
3.4 AMPK regulates glucose deprivation-induced degradation of CHK1 
 
AMPK is a key energy sensor and is activated under a variety of conditions including 
glucose starvation (Laderoute, 2006), and is composed of a catalytic α-subunit and two 
regulatory subunits (β and γ)(Hardie, 2012). Upon reduction in cellular energy levels, 
AMPK promotes ATP production by increasing the expression and activity of factors 
involved in catabolism while conserving energy by reducing biosynthetic pathways 
(Hardie, 2012). To determine if AMPK activity is important for regulating glucose 
deprivation-induced degradation of CHK1, we treated cells undergoing glucose 
deprivation with the AMPK inhibitor, Compound C (Hawley, 2002). Inhibiting AMPK 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
by Compound C, which led to the expected reduction in ACC phosphorylation, greatly 
reduced the loss of CHK1 in response to glucose deprivation in MDA-MB-231 and 
H1299 cells (Fig. 4A). We did not observe a change in CHK1 protein levels in response 
to glucose deprivation when we inhibited PI3K/AKT pathway with LY294002 (Fig. S3A-
B). Regulation of CHK1 by Compound C was not due to a change in CHK1 mRNA (Fig. 
4B), suggesting that pretreating with Compound C reduced CHK1 through a post-
transcriptional mechanism.  
 
To assess if the effect of Compound C treatment on CHK1 stability was through its 
regulation of AMPK, we next assessed CHK1 stability in cells where AMPK is depleted 
or knocked out. To deplete AMPK, we used two shRNAs targeting AMPK α1 and 
AMPK α2, respectively. shRNAs targeting AMPK α1 and AMPK α2 were each 
packaged into lentivirus, and cells were infected with both lentiviral preparations together 
to achieve knockdown of both AMPK α1 and AMPK α2. MDA-MB-231 cells were 
depleted of AMPK and assessed for CHK1 levels following glucose deprivation. We 
observed that depletion of AMPK blocked, in part, the reduction in CHK1 triggered by 
glucose deprivation (Fig. 4C), whereas we did not observe any effect on CHK1 protein in 
response to glucose deprivation when we depleted AKT1 (Fig. S3C). A similar 
stabilization of CHK1 in response to glucose deprivation was observed in MEFs that 
have both AMPK1 and AMPK2 knocked out (Fig. 4D). Similarly, when we depleted 
LKB1, and upstream activator of AMPK, we observed reduced degradation of CHK1 in 
response to glucose deprivation in MDA-MB-231, SK-BR3, and H1299 cells (Fig. 4E), 
consistent with the notion that the AMPK pathway is involved in regulating CHK1 
degradation in response to glucose deprivation.  
 
We next set out to determine if the small molecule activator of AMPK, AICAR, would 
increase the degradation of CHK1. By pre-treating SK-BR3 and H1299 cells with 
AICAR, and subsequently treating with cycloheximide under normal glucose conditions, 
we observed that activation of AMPK increased the rate of CHK1 degradation in cells 
(Fig. 4F). Furthermore, by depleting β-TrCP1 and β-TrCP2 in SK-BR3 and H1299 cells, 
we found that the ability of AICAR treatment to promote the degradation of CHK1 was 
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dependent on the presence of β-TrCP1 and/or β-TrCP2 (Fig. 4F). Our results therefore 
indicate that glucose deprivation regulates CHK1 degradation through increasing the 
activity of AMPK, suggesting that AMPK may regulate the ability of β-TrCP to target 
CHK1 for degradation, but the underlying mechanism remains elusive. 
 
3.5 AMPK phosphorylates CHK1 in the β-TrCP degron domain 
 
Recently, the transcription factor Gli1, which is increased in many human tumors, was 
shown to be regulated by an AMPK/β-TrCP pathway (Zhang, 2017). AMPK was shown 
to regulate the phosphorylation of Gli1, enhancing the binding between Gli1 and β-TrCP 
and the subsequent ubiquitination of Gli1. In addition, by analyzing the protein sequence 
of CHK1, Ser280 lies within an AMPK consensus phosphorylation site (RxxS/T) (Gwinn, 
2008; Zhang, 2016). To determine if CHK1 phosphorylation is increased in response to 
glucose deprivation, we grew MDA-MB-231 and SK-BR3 cells in either glucose 
containing or glucose-free conditions in which the degradation of CHK1 was blocked by 
treatment with MG132. Under these conditions we observed an increase in 
phosphorylation of CHK1 on Ser280 in both cell lines following glucose deprivation (Fig. 
5A and Fig. S4A). We next performed this assay in the presence of the inhibitor of 
AMPK, Compound C, and found that inhibiting AMPK blocked the glucose deprivation-
induced increase in CHK1 phosphorylation (Fig. 5B). To determine if AMPK purified 
from cells can directly phosphorylate CHK1, we pulled-down AMPK and incubated with 
CHK1 in an in vitro kinase assay. We found that AMPK pulled-down from cells was able 
to phosphorylate CHK1, which was dependent on AMPK activity as phosphorylation was 
reduced by expressing a dominant negative version of AMPK, as well as inhibited by 
pretreatment with the AMPK inhibitor Compound C (Fig. 5C). Furthermore, using mass 
spectrometry to identify residues on CHK1 that are phosphorylated by AMPK, we 
identified that phosphorylation on Ser284 was induced following co-expression with 
AMPK (Fig. 5D). In addition, AMPK is primarily located in the cytoplasm and CHK1 is 
thought to be resided mainly in the nucleus, while β-TrCP1 and β-TrCP2 are located at 
nucleus and cytoplasm respectively (Lassot, 2001). In order to assess whether all of these 
three proteins involved in regulating CHK1 degradation in response to glucose 
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deprivation are localized at the same subcellular compartment, we isolated nuclear and 
cytoplasmic fractions, and observed that AMPK did reside mainly in the cytoplasmic 
fractions under normal glucose and glucose-free conditions. Interestingly, CHK1 was 
present in both cytoplasmic and nuclear fractions regardless of glucose conditions (Fig. 
S4B). Given that Ser280 and Ser284
 
 are within the β-TrCP degron domain of CHK1, these 
results suggest that AMPK-mediated phosphorylation may directly promote the 
degradation of CHK1 by β-TrCP within the cytoplasm.  
3.6 Degradation of CHK1 is associated with reduced cell death in response to 
staurosporine 
 
CHK1 is a critical regulator of cell death, and therefore we assessed the CHK1 stability 
and cell death in response to treatment of MDA-MB-231 and SK-BR3 cells with the 
kinase inhibitor UCN-01, a staurosporine analog. We found that treating cells with 
increasing concentrations of UCN-01 lead to an increase in CHK1 degradation and which 
was further exacerbated in cells grown under glucose deprivation, resulting in enhanced 
cellular survival as marked by reduced levels of cleaved PARP (Fig. 5E). Enhanced cell 
survival in response to UCN-01 due to glucose deprivation was reversed by ectopic 
expression of CHK1 (Fig. 5E). Our results therefore indicate that glucose deprivation, 
which is observed in many solid tumors, promotes the degradation of CHK1 through an 
AMPK/β-TrCP pathway to promote cell survival (Fig. 5F).4 Discussion 
CHK1 is a critically important regulator of genomic integrity and therefore 
tumorigenesis. In this present study we have identified that CHK1 protein stability is 
altered during glucose deprivation, where the half-life of CHK1 is decreased in response 
to low glucose. These results are consistent with previous studies demonstrating 
increased degradation of CHK1 in response to glucose starvation (Kim, 2011), however 
the molecular mechanisms controlling CHK1 in a glucose-dependent manner have 
remained elusive. Here we report that in response to glucose deprivation, AMPK 
phosphorylates CHK1 at Ser280 within the β-TrCP degron motif. Phosphorylated CHK1 is 
then recognized by β-TrCP, followed by CHK1 ubiquitination and degradation. Our 
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results define the AMPK-CHK1-β-TrCP axis in regulation of CHK1 levels under glucose 
deprivation conditions. 
 
We found that CHK1 harbors a noncanonical β-TrCP degron motif, which when all three 
potential phosphorylation sites are mutated, leads to an increase in protein stability in 
response to glucose deprivation. Interestingly we observed that the S280A mutation of 
CHK1 had little or even an opposite effect on protein stability (which was observed in 
particular in the triple mutant). However, this triple mutant had reduced binding with, and 
ubiquitination by, β-TrCP (Fig. 3B-D). We suspect that this increase in degradation with 
this mutation may be due to altered subcellular localization due to phosphorylation at 
Ser280
 
, which has been shown to trigger nuclear localization of CHK1 (Li, 2012). 
Therefore, it is possible that this particular mutation may lead to an increased association 
with other E3 ubiquitin ligases targeting CHK1 leading to its reduced stability. 
Glucose sensing pathways have also been shown to regulate the ability of E3 ubiquitin 
ligases to recognize and target proteins for ubiquitination and degradation. Glucose 
deprivation or inhibition of glycolysis leads to decreased stability of HuR, Sp1, and 
Cyclin D1 through ubiquitination and subsequent degradation regulated by the E3 
ubiquitin ligase β-TrCP (Wei, 2008; Wei, 2009; Chu, 2012). In addition, AMPK, which 
is activated by low ATP levels, is also activated in response to low glucose (Zhang, 2017; 
Lin, 2018). Interestingly, AMPK activity has been shown to regulate the ability of β-
TrCP to recognize and ubiquitinate Gli1, a transcription factor that is involved in 
regulating glioblastoma tumorigenesis (Zhang, 2017).  
 
Our finding that β-TrCP targets CHK1 during glucose deprivation adds to a growing list 
of β-TrCP substrates that are targeted by this E3 ubiquitin ligase in a glucose-dependent 
manner, including HuR, Sp1, and Cyclin D1 (Wei, 2008; Wei, 2009; Chu, 2012). In 
addition, we have shown that the AMPK pathway, a critical energy sensor, targets CHK1 
for phosphorylation under glucose deprivation, suggesting that an AMPK/β-TrCP 
signaling axis may be a central component of cellular response to low glucose conditions. 
It would be of interest to assess whether AMPK is also involved in linking glucose levels 
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to degradation of HuR, Sp1 and Cyclin D1 by β-TrCP. In addition, given a potential role 
for an AMPK/β-TrCP pathway regulating Gli1 (Zhang, 2017) it would be interesting as 
well to test whether Gli1 stability is also regulated by glucose levels, as we have observed 
for CHK1. The fact that we saw limited effect by modulating Akt was somewhat 
surprising as Ser280 has been previously shown to be an Akt phosphorylation site in 
CHK1 (Puc, 2005). However, one might speculate that given the degron requires multiple 
phosphorylation sites, that phosphorylation at Ser280
 
 alone under Akt activation 
conditions might not be sufficient to drive recognition by β-TrCP, or alternatively Akt-
mediated phosphorylation may occur in contexts that do not allow for β-TrCP interaction. 
However, one might speculate that other signal transduction pathways may regulate 
CHK1 degradation either in a cell type specific or context-dependent manner, and 
therefore assessing additional kinase pathways may be of interest to elucidate more 
clearly how β-TrCP may be regulated under various conditions or contexts. 
5 Conclusions 
In summary, solid tumors exhibit glucose deprivation conditions due to increased glucose 
consumption as well as disorganized vascularization (Skinner, 1990; Bergers, 2003). 
Given their dependence on glucose for energy production, cancer cells must find ways to 
survive under these conditions, and how they do so has remained largely unknown. Here 
we show that CHK1, which is a critical regulator of genomic integrity due to its role in 
regulating DNA damage checkpoint signaling, is downregulated under glucose 
deprivation conditions through an AMPK/β-TrCP degradation pathway. Our study raises 
the possibility that under glucose deprivation, a hallmark of solid tumors, cells are 
allowed to continue cycling in an unchecked state leading to greater genomic instability 
and increase in mutation burden to promote cancer development.  
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Supplemental Information 
 
Fig. S1: Glucose deprivation induces ubiquitination of CHK1. 
 
Fig. S2: Degradation of CHK1 is largely dependent on a β-TrCP degron domain. 
 
Fig. S3: Inhibition of AKT does not influence glucose deprivation-induced  
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CHK1 degradation. 
 
Fig. S4: CHK1 is phosphorylated by AMPK upon glucose deprivation. 
 
 
Figure Legends 
Fig. 1. Cullin RING E3 ligases control CHK1 stability in response to glucose 
deprivation. (A) MDA-MB-231, SK-BR3, and H1299 cells were grown in normal 
glucose and glucose-free media and harvested at indicated times. Following lysis, protein 
was separated on SDS-PAGE and immunoblotted for CHK1, CHK2, p-AMPK, t-AMPK, 
p-AKT, t-AKT, p-ERK, t-ERK, p-GSK3β, t-GSK3α/β, and ACTIN. (B) MDA-MB-231, 
SK-BR3, and H1299 cells were transferred to glucose-free media containing 100 mg/ml 
cycloheximide (CHX) and either DMSO or 10 µM MG132 and harvested at indicated 
times. Following lysis, protein was separated on SDS-PAGE and immunoblotted for 
CHK1, and ACTIN. (C and D) MDA-MB-231, SK-BR3, and H1299 cells were grown in 
normal glucose and glucose-free media with increasing concentrations of MLN4924 for 
12 hrs (C), or with either DMSO or 1 µM MLN4924 for indicated times (D). Following 
lysis, protein was separated on SDS-PAGE and immunoblotted for CHK1, NEDD8, and 
ACTIN. (E) MDA-MB-231, SK-BR3, and H1299 cells were glucose-free media with 100 
mg/ml cycloheximide (CHX) and either DMSO or 1 µM MLN4924 and harvested at 
indicated times. Following lysis, protein was separated on SDS-PAGE and 
immunoblotted for CHK1, NEDD8, and ACTIN. “t-“ denotes antibodies that recognize 
total protein rather than a specifically modified version. 
 
Fig. 2. SCFβ-TrCP targets CHK1 for degradation under glucose deprivation. (A) 
HEK293 cells were transfected with vectors encoding indicated FLAG-tagged Cullin 
proteins. Cells were lysed and immunoprecipitated with agarose conjugated FLAG 
antibody. Immunoprecipitates and whole cell extracts were separated on SDS-PAGE and 
immunoblotted for CHK1, FLAG, and ACTIN. (B) MDA-MB-231 and H1299 cells 
transfected with siCtrl or siCUL1 and grown in glucose-free media with 100 mg/ml 
cycloheximide (CHX) for indicated times. Cells were harvested, lysed, and protein 
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separated on SDS-PAGE and immunoblotted for CHK1, NEDD8, and ACTIN. (C) 
HEK293 cells transfected with empty vector, FLAG-β-TrCP1, FLAG-FBXW7, or 
FLAG-SKP2, and grown in glucose-free media and treated with 10 µM MG132 for 12 
hrs. Cells were lysed and immunoprecipitated with agarose conjugated FLAG antibody. 
Immunoprecipitates and whole cell extracts were separated on SDS-PAGE and 
immunoblotted for CHK1, FLAG, and ACTIN. (D) MDA-MB-231, SK-BR3, and H1299 
were treated with normal glucose or glucose-free media along with 20 µM MG132 for 2 
hrs before harvest. Cells were lysed and immunoprecipitated with either IgG or CHK1 
antibody. Immunoprecipitates and whole cell extracts were separated on SDS-PAGE and 
immunoblotted for β-TrCP1, CHK1, and ACTIN. (E) MDA-MB-231, SK-BR3, and 
H1299 cells transfected with siCtrl or siβ-TrCP1+2 and grown in glucose-free media for 
indicated times. Cells were harvested, lysed, and protein separated on SDS-PAGE and 
immunoblotted for CHK1, β-TrCP1, and ACTIN. (F) MDA-MB-231, SK-BR3, and 
H1299 cells transfected with siCtrl or siβ-TrCP1+2 and grown in glucose-free media with 
100 mg/ml CHX for indicated times. Cells were harvested, lysed, and protein separated 
on SDS-PAGE and immunoblotted for CHK1, β-TrCP1, and ACTIN. (G) HEK293 cells 
were transfected with HA-CHK1, FLAG-β-TrCP1 WT, FLAG-β-TrCP1 ∆F, and His-Ub 
as indicated. Cells grown in glucose-free media and treated with 20 µM MG132 for 5.5 
hrs were lysed under denaturing conditions and Ub conjugated proteins were pulled down 
with Ni-NTA resin. Pull downs and whole cell extracts were separated on SDS-PAGE 
and immunoblotted for CHK1, FLAG, HA, and ACTIN. 
 
Fig. 3. Degradation of CHK1 is largely dependent on a β-TrCP1 degron domain. (A) 
CHK1 has a putative β-TrCP1 degron motif at amino acid 279-TSGGVS-284 in human, 
which is conserved among vertebrates. (B) Diagram of mutants of β-TrCP1 degron motif 
in CHK1 tested in panels B-D (Top). HEK293 cells transfected with empty vector, 
FLAG-CHK1 WT, FLAG-CHK1 S280A, FLAG-CHK1 S284A, or FLAG-CHK1 
T279A/S280A/S284A (3A). Cells were then transferred to glucose-free media and treated 
with 20 µM MG132 for 6 hrs. Cells were lysed and immunoprecipitated with agarose 
conjugated FLAG antibody. Immunoprecipitates and whole cell extracts were separated 
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on SDS-PAGE and immunoblotted for β-TrCP1, FLAG, and ACTIN (Bottom). (C) 
HEK293 cells were transfected with FLAG-CHK1 WT or FLAG-CHK1 T279A/S284A, 
HA-CHK1 or HA-CHK1 T279A/S280A/S284A, or HA-CHK1 S280A and grown in 
glucose-free media with 100 mg/ml CHX for indicated times. Cells were harvested, 
lysed, and protein separated on SDS-PAGE and immunoblotted for FLAG and ACTIN. 
(D) HEK293 cells were transfected with HA-β-TrCP1 with FLAG-CHK1, FLAG-CHK1 
S280A, FLAG-CHK1 S284A, or FLAG-CHK1 T279A/S280A/S284A, and His-Ub as 
indicated. Cells were grown in glucose-free media along with 20 µM MG132 for 6 hrs, 
and were lysed under denaturing conditions. Ub conjugated proteins were pulled down 
with Ni-NTA resin. Pull downs and whole cell extracts were separated on SDS-PAGE 
and immunoblotted for HA, FLAG, and ACTIN. 
 
Fig. 4. Inhibition of AMPK blocks glucose deprivation-induced CHK1 degradation. 
(A) Indicated cells growing in glucose containing media and treated with or without 
Compound C at 20 µM (MDA-MB-231 cells) or 40 µM (H1299 cells) for 1 hr, then 
transferred into glucose-free media with Compound C at the dose indicated above for 3.5 
hrs, upon which time CHX was added to 100 mg/ml for indicated times. Cells were 
harvested, lysed, and protein was separated on SDS-PAGE and immunoblotted for 
CHK1, p-ACC, and ACTIN. (B) Cells treated as in (A) were harvested prior to CHX 
treatment and RNA was extracted and subjected to RT-PCR for Chek1. Data generated 
from three independent replicates, error bars represent SEM, and a paired two-tailed 
Student’s t test was used to assess statistical significance. (C) MDA-MB-231 cells were 
transfected with shCtrl or a mixture of shRNAs targeting AMPK α1 and AMPK α2. 
Cells were transferred to glucose-free media and harvested at indicated times following 
addition of 100 mg/ml CHX. Cells were harvested, lysed, and protein separated on SDS-
PAGE and immunoblotted for CHK1, p-ACC, t-ACC, p-AMPK, t-AMPK, and ACTIN. 
(D) WT and Double AMPK KO (DKO) MEFs where grown in glucose-free media for 
indicated times with 100 mg/ml CHX. Cells were harvested, lysed, and protein separated 
on SDS-PAGE and immunoblotted for CHK1, p-AMPK, t-AMPK, and ACTIN. (E) 
MDA-MB-231, SK-BR3, and H1299 cells were transfected with siCtrl or siLKB1 and 
grown in glucose-free media for indicated times with 100 mg/ml CHX. Cells were 
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harvested, lysed, and protein separated on SDS-PAGE and immunoblotted for CHK1, 
LKB1, p-AMPK, and ACTIN. (F) SK-BR3 and H1299 cells expressing siCtrl or siβ-
TrCP1+2 were treated with DMSO or 0.5 mM AICAR for 12 hrs and subsequently CHX 
was added to 100 mg/ml for indicated times. Cells were harvested, lysed, and protein was 
separated on SDS-PAGE and immunoblotted for CHK1, p-ACC, t-ACC, β-TrCP1, and 
ACTIN. 
Fig. 5. CHK1 is phosphorylated by AMPK upon glucose deprivation to govern 
cancer cell survival. (A) MDA-MB-231 cells were grown in normal glucose and 
glucose-free media in the presence of 10 µM MG132 and harvested at indicated times. 
Following lysis, protein was separated on SDS-PAGE and immunoblotted for p-CHK1 
(S280), t-CHK1, and ACTIN. (B) MDA-MB-231 cells pre-treated with either DMSO or 
Compound C (20μM) for 1 hr ,and then transferred into glucose-free media with 
Compound C at the dose indicated above for 3.5 hrs , followed by addition of MG132 to 
a final concentration of 10 µM and harvested at indicated times. Following lysis, protein 
was separated on SDS-PAGE and immunoblotted for p-CHK1, t-CHK1, p-ACC, t-ACC 
and ACTIN. (C) HEK293 cells were transfected with empty vector, FLAG-AMPK α2 
WT, FLAG-AMPK α1 Dominant Negative (DN), or HA-CHK1. Cells were lysed and 
immunoprecipitated with agarose conjugated FLAG antibody and HA antibody. 
Immunoprecipitates were processed and incubated together in an in vitro kinase assay in 
the absence or presence of Compound C as indicated and as described in the materials 
and methods section. Proteins were separated on SDS-PAGE and immunoblotted for p-
CHK1, HA, and FLAG. (D) Schematic diagram including previously identified 
phosphorylation sites in CHK1 (top)(Goto, 2015) of detected phosphorylation sites of 
CHK1 in the absence (middle) or presence (bottom) of ectopic expression of AMKP as 
described in the materials and methods. (E) Indicated cells ectopically expressing control 
vector or FLAG-CHK1 were grown in glucose containing or glucose-free media with 
increasing concentrations of UCN-01 for 9 hrs (MDA-MB-231) or 6 hrs (SK-BR3). 
Following lysis, protein was separated on SDS-PAGE and immunoblotted for PARP, 
CHK1, and ACTIN. (F) Diagram depicting regulation of CHK1 degradation under 
glucose deprivation by an AMPK/β-TrCP pathway. 
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